OXFORD, United Kingdom, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Pamure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | ksharma@macbiocom.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | summit@consilium-comms.com | |
| Philippa Gardner / Rosie Philips | ||
-END-